Atea Pharmaceuticals Inc - Asset Resilience Ratio
Atea Pharmaceuticals Inc (AVIR) has an Asset Resilience Ratio of 65.39% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore AVIR total assets for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Atea Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See Atea Pharmaceuticals Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Atea Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AVIR market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $206.12 Million | 65.39% |
| Total Liquid Assets | $206.12 Million | 65.39% |
Asset Resilience Insights
- Very High Liquidity: Atea Pharmaceuticals Inc maintains exceptional liquid asset reserves at 65.39% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Atea Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Atea Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Atea Pharmaceuticals Inc (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Atea Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 65.39% | $206.12 Million | $315.22 Million | -18.55pp |
| 2024-12-31 | 83.94% | $390.02 Million | $464.67 Million | +10.94pp |
| 2023-12-31 | 72.99% | $434.28 Million | $594.97 Million | +4.26pp |
| 2022-12-31 | 68.73% | $458.25 Million | $666.71 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $772.89 Million | -- |
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company … Read more